J&J’s Zytiga –The Anatomy Of A Cancer Launch
Executive Summary
Johnson & Johnson’s prostate cancer drug Zytiga is off to a brilliant launch. Payors are covering it with relatively few restrictions, medical oncologists are using it in advanced patients, and it has streaked ahead of its direct competitor Jevtana, a second-generation taxane, in part by grabbing new patient share from the same post-docetaxel population.
You may also be interested in...
J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A
Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.
Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.
J&J Touts New Product Strength In 2012 Year-End Call
The global pharmaceutical giant has had several new products hit the market in the last two years that have allowed it to retain a global leadership position despite tough economic circumstances and issues with its consumer segment.